Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
JPMorgan Chase & Co. and its affiliates have emerged as a substantial holder in Clinuvel Pharmaceuticals Limited, securing a 5.10% stake with over 2.5 million ordinary shares. This development, officially reported on August 20, 2024, signifies JPMorgan’s notable interest in the pharmaceutical company, potentially influencing investor confidence and Clinuvel’s stock market performance.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
